Servier Offers $483 Million To Buy Rest Of Hungarian Generics Maker Egis
This article was originally published in The Pink Sheet Daily
Executive Summary
After holding a 51% stake in Egis for 18 years, France's mid-sized pharma company Servier is now offering nearly $483 million to buy the rest of the Hungarian generics company.
You may also be interested in...
Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
Korea's Celltrion Signs Deal with Hungary's Egis Pharmaceuticals to Sell Biosimilars In Former Soviet Republic Countries, Eastern Europe
SEOUL - South Korea's Celltrion has signed a deal with Hungary's Egis Pharmaceuticals to sell Celltrion's future biosimilar products in the former Soviet Republic countries and Eastern Union
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.